NYSEAMERICAN:AMPE - Ampio Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.45 -0.02 (-4.26 %) (As of 10/18/2018 05:16 AM ET)Previous Close$0.47Today's Range$0.44 - $0.4752-Week Range$0.35 - $4.95Volume660,200 shsAverage Volume1.49 million shsMarket Capitalization$197.70 millionP/E RatioN/ADividend YieldN/ABeta0.51 Company ProfileDiscussionChartEarnings HistoryFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, an oral agent for the treatment of diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado. Receive AMPE News and Ratings via Email Sign-up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryPharmaceuticals SectorMedical SymbolNYSEAMERICAN:AMPE CUSIP03209T10 Webampiopharma.com Phone+1-720-4376500 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on Equity-965.03% Return on Assets-151.95% Miscellaneous EmployeesN/A Outstanding Shares106,540,000Market Cap$197.70 million Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Frequently Asked Questions What is Ampio Pharmaceuticals' stock symbol? Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE." How were Ampio Pharmaceuticals' earnings last quarter? Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) released its quarterly earnings results on Tuesday, August, 14th. The specialty pharmaceutical company reported $0.05 earnings per share for the quarter. View Ampio Pharmaceuticals' Earnings History. When is Ampio Pharmaceuticals' next earnings date? Ampio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Ampio Pharmaceuticals. Are investors shorting Ampio Pharmaceuticals? Ampio Pharmaceuticals saw a increase in short interest in September. As of September 28th, there was short interest totalling 15,243,665 shares, an increase of 6.2% from the September 14th total of 14,359,784 shares. Based on an average daily trading volume, of 1,381,893 shares, the short-interest ratio is currently 11.0 days. Currently, 15.5% of the shares of the company are short sold. View Ampio Pharmaceuticals' Current Options Chain. Who are some of Ampio Pharmaceuticals' key competitors? Some companies that are related to Ampio Pharmaceuticals include Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Wellness Solutions (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD) and IMV (IMV). Who are Ampio Pharmaceuticals' key executives? Ampio Pharmaceuticals' management team includes the folowing people: Mr. Michael E. Macaluso, Founder, Chairman & CEO (Age 66)Mr. Thomas E. Chilcott III, CFO, Treasurer & Sec. (Age 50)Ms. Holli Cherevka, Chief Operating Officer (Age 35)Dr. David Bar-Or, Chief Scientific Officer, Member of Scientific Advisory Board & Director (Age 69) Who are Ampio Pharmaceuticals' major shareholders? Ampio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Courier Capital LLC (0.29%). View Institutional Ownership Trends for Ampio Pharmaceuticals. Which institutional investors are buying Ampio Pharmaceuticals stock? AMPE stock was purchased by a variety of institutional investors in the last quarter, including Courier Capital LLC. View Insider Buying and Selling for Ampio Pharmaceuticals. How do I buy shares of Ampio Pharmaceuticals? Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ampio Pharmaceuticals' stock price today? One share of AMPE stock can currently be purchased for approximately $0.45. How big of a company is Ampio Pharmaceuticals? Ampio Pharmaceuticals has a market capitalization of $197.70 million. What is Ampio Pharmaceuticals' official website? The official website for Ampio Pharmaceuticals is http://ampiopharma.com/. How can I contact Ampio Pharmaceuticals? Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The specialty pharmaceutical company can be reached via phone at +1-720-4376500. MarketBeat Community Rating for Ampio Pharmaceuticals (NYSEAMERICAN AMPE)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 107 (Vote Outperform)Underperform Votes: 108 (Vote Underperform)Total Votes: 215MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/18/2018 by MarketBeat.com StaffFeatured Article: Do stock splits help investors?